Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1987 2
1988 1
1990 4
1991 10
1992 14
1993 20
1994 18
1995 45
1996 31
1997 58
1998 78
1999 111
2000 109
2001 139
2002 185
2003 192
2004 215
2005 228
2006 272
2007 303
2008 331
2009 350
2010 420
2011 474
2012 482
2013 646
2014 671
2015 706
2016 724
2017 716
2018 728
2019 725
2020 391
Text availability
Article attribute
Article type
Publication date

Search Results

8,398 results
Results by year
Filters applied: . Clear all
Page 1
Inflammatory Bowel Disease.
Lichtiger S. Lichtiger S. Gastrointest Endosc Clin N Am. 2019 Jul;29(3):xv-xvi. doi: 10.1016/j.giec.2019.03.002. Epub 2019 Apr 12. Gastrointest Endosc Clin N Am. 2019. PMID: 31078255 No abstract available.
Inflammatory bowel disease and the elderly: a review.
Taleban S, Colombel JF, Mohler MJ, Fain MJ. Taleban S, et al. J Crohns Colitis. 2015 Jun;9(6):507-15. doi: 10.1093/ecco-jcc/jjv059. Epub 2015 Apr 13. J Crohns Colitis. 2015. PMID: 25870198 Review.
Inflammatory bowel disease among the elderly is common, with growing incident and prevalence rates. Compared with younger IBD patients, genetics contribute less to the pathogenesis of older-onset IBD, with dysbiosis and dysregulation of the immune system play
Inflammatory bowel disease among the elderly is common, with growing incident and prevalence rates. Compared with young
Intestinal Permeability in Inflammatory Bowel Disease: Pathogenesis, Clinical Evaluation, and Therapy of Leaky Gut.
Michielan A, D'Incà R. Michielan A, et al. Mediators Inflamm. 2015;2015:628157. doi: 10.1155/2015/628157. Epub 2015 Oct 25. Mediators Inflamm. 2015. PMID: 26582965 Free PMC article. Review.
The pathogenesis of inflammatory bowel disease (IBD) is multifactorial with data suggesting the role of a disturbed interaction between the gut and the intestinal microbiota. ...Antitumor necrosis factor-α (TNF-α) therapy reduces mucosal inflamm …
The pathogenesis of inflammatory bowel disease (IBD) is multifactorial with data suggesting the role of a disturbed int …
Inflammatory Bowel Disease: Pathophysiology and Current Therapeutic Approaches.
Abraham BP, Ahmed T, Ali T. Abraham BP, et al. Handb Exp Pharmacol. 2017;239:115-146. doi: 10.1007/164_2016_122. Handb Exp Pharmacol. 2017. PMID: 28233184 Review.
Inflammatory bowel diseases, most commonly categorized as Crohn's disease and ulcerative colitis, are immune mediated chronic inflammatory disorders of the gastrointestinal tract. ...In the end, therapeutic algorithms for both diseases ar
Inflammatory bowel diseases, most commonly categorized as Crohn's disease and ulcerative colitis, are immune med
Novel therapeutic targets for inflammatory bowel disease.
Argollo M, Fiorino G, Hindryckx P, Peyrin-Biroulet L, Danese S. Argollo M, et al. J Autoimmun. 2017 Dec;85:103-116. doi: 10.1016/j.jaut.2017.07.004. Epub 2017 Jul 12. J Autoimmun. 2017. PMID: 28711286 Review.
Inflammatory bowel disease (IBD), including Crohn's disease (CD) and Ulcerative Colitis (UC), are immune mediated conditions associated with progressive damage of the inflamed gut tissue, and have a considerable impact on the patient's quality of life.
Inflammatory bowel disease (IBD), including Crohn's disease (CD) and Ulcerative Colitis (UC), are immune mediate
Induction and maintenance treatment of inflammatory bowel disease: A comprehensive review.
Jeong DY, Kim S, Son MJ, Son CY, Kim JY, Kronbichler A, Lee KH, Shin JI. Jeong DY, et al. Autoimmun Rev. 2019 May;18(5):439-454. doi: 10.1016/j.autrev.2019.03.002. Epub 2019 Mar 4. Autoimmun Rev. 2019. PMID: 30844556 Review.
Ulcerative colitis (UC) and Crohn's disease (CD) are the two major types of inflammatory bowel disease (IBD). We conducted a comprehensive review of meta-analyses to summarize the reported effectiveness of different drugs for IBD. ...
Ulcerative colitis (UC) and Crohn's disease (CD) are the two major types of inflammatory bowel disease (IBD). We …
Emerging biologics in inflammatory bowel disease.
Chan HC, Ng SC. Chan HC, et al. J Gastroenterol. 2017 Feb;52(2):141-150. doi: 10.1007/s00535-016-1283-0. Epub 2016 Nov 10. J Gastroenterol. 2017. PMID: 27832357 Review.
Early biologic therapy is recommended in patients with inflammatory bowel disease and poor prognostic factors and in those refractory to conventional medications. Anti-tumor necrosis factor (anti-TNF) agents are the most commonly used bio …
Early biologic therapy is recommended in patients with inflammatory bowel disease and poor prognostic factors and in th …
Recent advances in understanding and managing pediatric inflammatory bowel disease.
Gurram B, Patel AS. Gurram B, et al. F1000Res. 2019 Dec 13;8:F1000 Faculty Rev-2097. doi: 10.12688/f1000research.19609.1. eCollection 2019. F1000Res. 2019. PMID: 31885858 Free PMC article. Review.
Though anti-tumor necrosis factor agents have been the primary therapy over the last decade, recently there has been an expansion of therapeutic targets and alternative mechanism of action drugs with a focus on individualized and personalized therapy. ...As s …
Though anti-tumor necrosis factor agents have been the primary therapy over the last decade, recently there has been an …
Biological therapies in inflammatory bowel disease: Beyond anti-TNF therapies.
Katsanos KH, Papamichael K, Feuerstein JD, Christodoulou DK, Cheifetz AS. Katsanos KH, et al. Clin Immunol. 2019 Sep;206:9-14. doi: 10.1016/j.clim.2018.03.004. Epub 2018 Mar 12. Clin Immunol. 2019. PMID: 29545207
The pharmacological management of inflammatory bowel disease (IBD) over the last two decades has transitioned from reliance on aminosalycilates, corticosteroids and immunomodulators to earlier treatment with anti-tumor necrosis factor (an …
The pharmacological management of inflammatory bowel disease (IBD) over the last two decades has transitioned from reli …
Management of Inflammatory Bowel Disease: Progress and Promise.
Lightdale CJ. Lightdale CJ. Gastrointest Endosc Clin N Am. 2019 Jul;29(3):xiii-xiv. doi: 10.1016/j.giec.2019.03.003. Gastrointest Endosc Clin N Am. 2019. PMID: 31078254 No abstract available.
8,398 results
Jump to page
Feedback